SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
REHOVOT, Israel, Feb. 27, 2017 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 37th Annual Health Care Conference taking place in Boston, Massachusetts from March 6 – 8, 2017. Dr. Lieberman’s presentation will take place on Monday, March 6 at 2:00pm ET.
- 29th Annual ROTH Conference taking place in Dana Point, California from March 12 – 15, 2017. Dr. Lieberman’s presentation will take place on Tuesday, March 14 at 9:00am PT, 12:00pm ET.
To access the live webcast of the presentation, please visit ir.neuroderm.com/. A replay will be available for a limited time following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
[email protected]
Tel.: +972-8-946 2729;
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1768
